Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and sézary syndrome: Effect of specific prognostic markers on survival and development of a prognostic model

Julia J. Scarisbrick; H. Miles Prince; Maarten H. Vermeer; Pietro Quaglino; Steven Horwitz; Pierluigi Porcu; Rudolf Stadler; Gary S. Wood; Marie Beylot-Barry; Anne Pham-Ledard; Francine Foss; Michael Girardi; Martine Bagot; Laurence Michel; Maxime Battistella; Joan Guitart; Timothy M. Kuzel; Maria Estela Martinez-Escala; Teresa Estrach; Evangelia Papadavid; Christina Antoniou; Dimitis Rigopoulos; Vassilki Nikolaou; Makoto Sugaya; Tomomitsu Miyagaki; Robert Gniadecki; José Antonio Sanches; Jade Cury-Martins; Denis Miyashiro; Octavio Servitje; Cristina Muniesa; Emilio Berti; Francesco Onida; Laura Corti; Emilia Hodak; Iris Amitay-Laish; Pablo L. Ortiz-Romero; Jose L. Rodríguez-Peralto; Robert Knobler; Stefanie Porkert; Wolfgang Bauer; Nicola Pimpinelli; Vieri Grandi; Richard Cowan; Alain Rook; Ellen Kim; Alessandro Pileri; Annalisa Patrizi; Ramon M. Pujol; Henry Wong; Kelly Tyler; Rene Stranzenbach; Christiane Querfeld; Paolo Fava; Milena Maule; Rein Willemze; Felicity Evison; Stephen Morris; Robert Twigger; Rakhshandra Talpur; Jinah Kim; Grant Ognibene; Shufeng Li; Mahkam Tavallaee; Richard T. Hoppe; Madeleine Duvic; Sean J. Whittaker; Youn H. Kim

doi:10.1200/JCO.2015.61.7142

Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and sézary syndrome: Effect of specific prognostic markers on survival and development of a prognostic model

Julia J. Scarisbrick^*, H. Miles Prince, Maarten H. Vermeer, Pietro Quaglino, Steven Horwitz, Pierluigi Porcu, Rudolf Stadler, Gary S. Wood, Marie Beylot-Barry, Anne Pham-Ledard, Francine Foss, Michael Girardi, Martine Bagot, Laurence Michel, Maxime Battistella, Joan Guitart, Timothy M. Kuzel, Maria Estela Martinez-Escala, Teresa Estrach, Evangelia PapadavidChristina Antoniou, Dimitis Rigopoulos, Vassilki Nikolaou, Makoto Sugaya, Tomomitsu Miyagaki, Robert Gniadecki, José Antonio Sanches, Jade Cury-Martins, Denis Miyashiro, Octavio Servitje, Cristina Muniesa, Emilio Berti, Francesco Onida, Laura Corti, Emilia Hodak, Iris Amitay-Laish, Pablo L. Ortiz-Romero, Jose L. Rodríguez-Peralto, Robert Knobler, Stefanie Porkert, Wolfgang Bauer, Nicola Pimpinelli, Vieri Grandi, Richard Cowan, Alain Rook, Ellen Kim, Alessandro Pileri, Annalisa Patrizi, Ramon M. Pujol, Henry Wong, Kelly Tyler, Rene Stranzenbach, Christiane Querfeld, Paolo Fava, Milena Maule, Rein Willemze, Felicity Evison, Stephen Morris, Robert Twigger, Rakhshandra Talpur, Jinah Kim, Grant Ognibene, Shufeng Li, Mahkam Tavallaee, Richard T. Hoppe, Madeleine Duvic, Sean J. Whittaker, Youn H. Kim

^*Corresponding author for this work

Dermatology

Research output: Contribution to journal › Article › peer-review

328 Scopus citations

Abstract

Purpose: Advanced-stage mycosis fungoides (MF; stage IIB to IV) and Sézary syndrome (SS) are aggressive lymphomas with a median survival of 1 to 5 years. Clinical management is stage based; however, there is wide range of outcome within stages. Published prognostic studies in MF/SS have been single-center trials. Because of the rarity of MF/SS, only a large collaboration would power a study to identify independent prognostic markers Patients and Methods: Literature review identified the following 10 candidate markers: stage, age, sex, cutaneous histologic features of folliculotropism, CD30 positivity, proliferation index, large-cell transformation, WBC/lymphocyte count, serum lactate dehydrogenase, and identical T-cell clone in blood and skin. Data were collected at specialist centers on patients diagnosed with advanced-stage MF/SS from 2007. Each parameter recorded at diagnosis was tested against overall survival (OS) Results: Staging data on 1,275 patients with advanced MF/SS from 29 international sites were included for survival analysis. The median OS was 63 months, with 2- and 5-year survival rates of 77% and 52%, respectively. The median OS for patients with stage IIB disease was 68 months, but patients diagnosed with stage III disease had slightly improved survival compared with patients with stage IB, although patients diagnosed with stage IV disease had significantly worse survival (48 months for stage IVA and 33 months for stage IVB). Of the 10 variables tested, four (stage IV, age > 60 years, large-cell transformation, and increased lactate dehydrogenase) were independent prognostic markers for a worse survival. Combining these four factors in a prognostic index model identified the following three risk groups across stages with significantly different 5-year surviva rates: low risk (68%), intermediate risk (44%), and high risk (28%) Conclusion: To our knowledge, this study includes the largest cohort of patients with advanced-stage MF/SS and identifies markers with independent prognostic value, which, used together in a prognostic ndex, may be useful to stratify advanced-stage patients.

Original language	English (US)
Pages (from-to)	3766-3773
Number of pages	8
Journal	Journal of Clinical Oncology
Volume	33
Issue number	32
DOIs	https://doi.org/10.1200/JCO.2015.61.7142
State	Published - Nov 10 2015

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/JCO.2015.61.7142

Fingerprint

Dive into the research topics of 'Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and sézary syndrome: Effect of specific prognostic markers on survival and development of a prognostic model'. Together they form a unique fingerprint.

Cite this

Scarisbrick, J. J., Prince, H. M., Vermeer, M. H., Quaglino, P., Horwitz, S., Porcu, P., Stadler, R., Wood, G. S., Beylot-Barry, M., Pham-Ledard, A., Foss, F., Girardi, M., Bagot, M., Michel, L., Battistella, M., Guitart, J., Kuzel, T. M., Martinez-Escala, M. E., Estrach, T., ... Kim, Y. H. (2015). Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and sézary syndrome: Effect of specific prognostic markers on survival and development of a prognostic model. Journal of Clinical Oncology, 33(32), 3766-3773. https://doi.org/10.1200/JCO.2015.61.7142

@article{949ad1ecb0bb442a8bffd8f2ce3514ee,

title = "Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and s{\'e}zary syndrome: Effect of specific prognostic markers on survival and development of a prognostic model",

abstract = "Purpose: Advanced-stage mycosis fungoides (MF; stage IIB to IV) and S{\'e}zary syndrome (SS) are aggressive lymphomas with a median survival of 1 to 5 years. Clinical management is stage based; however, there is wide range of outcome within stages. Published prognostic studies in MF/SS have been single-center trials. Because of the rarity of MF/SS, only a large collaboration would power a study to identify independent prognostic markers Patients and Methods: Literature review identified the following 10 candidate markers: stage, age, sex, cutaneous histologic features of folliculotropism, CD30 positivity, proliferation index, large-cell transformation, WBC/lymphocyte count, serum lactate dehydrogenase, and identical T-cell clone in blood and skin. Data were collected at specialist centers on patients diagnosed with advanced-stage MF/SS from 2007. Each parameter recorded at diagnosis was tested against overall survival (OS) Results: Staging data on 1,275 patients with advanced MF/SS from 29 international sites were included for survival analysis. The median OS was 63 months, with 2- and 5-year survival rates of 77% and 52%, respectively. The median OS for patients with stage IIB disease was 68 months, but patients diagnosed with stage III disease had slightly improved survival compared with patients with stage IB, although patients diagnosed with stage IV disease had significantly worse survival (48 months for stage IVA and 33 months for stage IVB). Of the 10 variables tested, four (stage IV, age > 60 years, large-cell transformation, and increased lactate dehydrogenase) were independent prognostic markers for a worse survival. Combining these four factors in a prognostic index model identified the following three risk groups across stages with significantly different 5-year surviva rates: low risk (68%), intermediate risk (44%), and high risk (28%) Conclusion: To our knowledge, this study includes the largest cohort of patients with advanced-stage MF/SS and identifies markers with independent prognostic value, which, used together in a prognostic ndex, may be useful to stratify advanced-stage patients.",

author = "Scarisbrick, {Julia J.} and Prince, {H. Miles} and Vermeer, {Maarten H.} and Pietro Quaglino and Steven Horwitz and Pierluigi Porcu and Rudolf Stadler and Wood, {Gary S.} and Marie Beylot-Barry and Anne Pham-Ledard and Francine Foss and Michael Girardi and Martine Bagot and Laurence Michel and Maxime Battistella and Joan Guitart and Kuzel, {Timothy M.} and Martinez-Escala, {Maria Estela} and Teresa Estrach and Evangelia Papadavid and Christina Antoniou and Dimitis Rigopoulos and Vassilki Nikolaou and Makoto Sugaya and Tomomitsu Miyagaki and Robert Gniadecki and Sanches, {Jos{\'e} Antonio} and Jade Cury-Martins and Denis Miyashiro and Octavio Servitje and Cristina Muniesa and Emilio Berti and Francesco Onida and Laura Corti and Emilia Hodak and Iris Amitay-Laish and Ortiz-Romero, {Pablo L.} and Rodr{\'i}guez-Peralto, {Jose L.} and Robert Knobler and Stefanie Porkert and Wolfgang Bauer and Nicola Pimpinelli and Vieri Grandi and Richard Cowan and Alain Rook and Ellen Kim and Alessandro Pileri and Annalisa Patrizi and Pujol, {Ramon M.} and Henry Wong and Kelly Tyler and Rene Stranzenbach and Christiane Querfeld and Paolo Fava and Milena Maule and Rein Willemze and Felicity Evison and Stephen Morris and Robert Twigger and Rakhshandra Talpur and Jinah Kim and Grant Ognibene and Shufeng Li and Mahkam Tavallaee and Hoppe, {Richard T.} and Madeleine Duvic and Whittaker, {Sean J.} and Kim, {Youn H.}",

note = "Publisher Copyright: {\textcopyright} 2015 by American Society of Clinical Oncology.",

year = "2015",

month = nov,

day = "10",

doi = "10.1200/JCO.2015.61.7142",

language = "English (US)",

volume = "33",

pages = "3766--3773",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

number = "32",

}

Scarisbrick, JJ, Prince, HM, Vermeer, MH, Quaglino, P, Horwitz, S, Porcu, P, Stadler, R, Wood, GS, Beylot-Barry, M, Pham-Ledard, A, Foss, F, Girardi, M, Bagot, M, Michel, L, Battistella, M, Guitart, J, Kuzel, TM, Martinez-Escala, ME, Estrach, T, Papadavid, E, Antoniou, C, Rigopoulos, D, Nikolaou, V, Sugaya, M, Miyagaki, T, Gniadecki, R, Sanches, JA, Cury-Martins, J, Miyashiro, D, Servitje, O, Muniesa, C, Berti, E, Onida, F, Corti, L, Hodak, E, Amitay-Laish, I, Ortiz-Romero, PL, Rodríguez-Peralto, JL, Knobler, R, Porkert, S, Bauer, W, Pimpinelli, N, Grandi, V, Cowan, R, Rook, A, Kim, E, Pileri, A, Patrizi, A, Pujol, RM, Wong, H, Tyler, K, Stranzenbach, R, Querfeld, C, Fava, P, Maule, M, Willemze, R, Evison, F, Morris, S, Twigger, R, Talpur, R, Kim, J, Ognibene, G, Li, S, Tavallaee, M, Hoppe, RT, Duvic, M, Whittaker, SJ & Kim, YH 2015, 'Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and sézary syndrome: Effect of specific prognostic markers on survival and development of a prognostic model', Journal of Clinical Oncology, vol. 33, no. 32, pp. 3766-3773. https://doi.org/10.1200/JCO.2015.61.7142

Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and sézary syndrome: Effect of specific prognostic markers on survival and development of a prognostic model. / Scarisbrick, Julia J.; Prince, H. Miles; Vermeer, Maarten H. et al.
In: Journal of Clinical Oncology, Vol. 33, No. 32, 10.11.2015, p. 3766-3773.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and sézary syndrome

T2 - Effect of specific prognostic markers on survival and development of a prognostic model

AU - Scarisbrick, Julia J.

AU - Prince, H. Miles

AU - Vermeer, Maarten H.

AU - Quaglino, Pietro

AU - Horwitz, Steven

AU - Porcu, Pierluigi

AU - Stadler, Rudolf

AU - Wood, Gary S.

AU - Beylot-Barry, Marie

AU - Pham-Ledard, Anne

AU - Foss, Francine

AU - Girardi, Michael

AU - Bagot, Martine

AU - Michel, Laurence

AU - Battistella, Maxime

AU - Guitart, Joan

AU - Kuzel, Timothy M.

AU - Martinez-Escala, Maria Estela

AU - Estrach, Teresa

AU - Papadavid, Evangelia

AU - Antoniou, Christina

AU - Rigopoulos, Dimitis

AU - Nikolaou, Vassilki

AU - Sugaya, Makoto

AU - Miyagaki, Tomomitsu

AU - Gniadecki, Robert

AU - Sanches, José Antonio

AU - Cury-Martins, Jade

AU - Miyashiro, Denis

AU - Servitje, Octavio

AU - Muniesa, Cristina

AU - Berti, Emilio

AU - Onida, Francesco

AU - Corti, Laura

AU - Hodak, Emilia

AU - Amitay-Laish, Iris

AU - Ortiz-Romero, Pablo L.

AU - Rodríguez-Peralto, Jose L.

AU - Knobler, Robert

AU - Porkert, Stefanie

AU - Bauer, Wolfgang

AU - Pimpinelli, Nicola

AU - Grandi, Vieri

AU - Cowan, Richard

AU - Rook, Alain

AU - Kim, Ellen

AU - Pileri, Alessandro

AU - Patrizi, Annalisa

AU - Pujol, Ramon M.

AU - Wong, Henry

AU - Tyler, Kelly

AU - Stranzenbach, Rene

AU - Querfeld, Christiane

AU - Fava, Paolo

AU - Maule, Milena

AU - Willemze, Rein

AU - Evison, Felicity

AU - Morris, Stephen

AU - Twigger, Robert

AU - Talpur, Rakhshandra

AU - Kim, Jinah

AU - Ognibene, Grant

AU - Li, Shufeng

AU - Tavallaee, Mahkam

AU - Hoppe, Richard T.

AU - Duvic, Madeleine

AU - Whittaker, Sean J.

AU - Kim, Youn H.

PY - 2015/11/10

Y1 - 2015/11/10

N2 - Purpose: Advanced-stage mycosis fungoides (MF; stage IIB to IV) and Sézary syndrome (SS) are aggressive lymphomas with a median survival of 1 to 5 years. Clinical management is stage based; however, there is wide range of outcome within stages. Published prognostic studies in MF/SS have been single-center trials. Because of the rarity of MF/SS, only a large collaboration would power a study to identify independent prognostic markers Patients and Methods: Literature review identified the following 10 candidate markers: stage, age, sex, cutaneous histologic features of folliculotropism, CD30 positivity, proliferation index, large-cell transformation, WBC/lymphocyte count, serum lactate dehydrogenase, and identical T-cell clone in blood and skin. Data were collected at specialist centers on patients diagnosed with advanced-stage MF/SS from 2007. Each parameter recorded at diagnosis was tested against overall survival (OS) Results: Staging data on 1,275 patients with advanced MF/SS from 29 international sites were included for survival analysis. The median OS was 63 months, with 2- and 5-year survival rates of 77% and 52%, respectively. The median OS for patients with stage IIB disease was 68 months, but patients diagnosed with stage III disease had slightly improved survival compared with patients with stage IB, although patients diagnosed with stage IV disease had significantly worse survival (48 months for stage IVA and 33 months for stage IVB). Of the 10 variables tested, four (stage IV, age > 60 years, large-cell transformation, and increased lactate dehydrogenase) were independent prognostic markers for a worse survival. Combining these four factors in a prognostic index model identified the following three risk groups across stages with significantly different 5-year surviva rates: low risk (68%), intermediate risk (44%), and high risk (28%) Conclusion: To our knowledge, this study includes the largest cohort of patients with advanced-stage MF/SS and identifies markers with independent prognostic value, which, used together in a prognostic ndex, may be useful to stratify advanced-stage patients.

AB - Purpose: Advanced-stage mycosis fungoides (MF; stage IIB to IV) and Sézary syndrome (SS) are aggressive lymphomas with a median survival of 1 to 5 years. Clinical management is stage based; however, there is wide range of outcome within stages. Published prognostic studies in MF/SS have been single-center trials. Because of the rarity of MF/SS, only a large collaboration would power a study to identify independent prognostic markers Patients and Methods: Literature review identified the following 10 candidate markers: stage, age, sex, cutaneous histologic features of folliculotropism, CD30 positivity, proliferation index, large-cell transformation, WBC/lymphocyte count, serum lactate dehydrogenase, and identical T-cell clone in blood and skin. Data were collected at specialist centers on patients diagnosed with advanced-stage MF/SS from 2007. Each parameter recorded at diagnosis was tested against overall survival (OS) Results: Staging data on 1,275 patients with advanced MF/SS from 29 international sites were included for survival analysis. The median OS was 63 months, with 2- and 5-year survival rates of 77% and 52%, respectively. The median OS for patients with stage IIB disease was 68 months, but patients diagnosed with stage III disease had slightly improved survival compared with patients with stage IB, although patients diagnosed with stage IV disease had significantly worse survival (48 months for stage IVA and 33 months for stage IVB). Of the 10 variables tested, four (stage IV, age > 60 years, large-cell transformation, and increased lactate dehydrogenase) were independent prognostic markers for a worse survival. Combining these four factors in a prognostic index model identified the following three risk groups across stages with significantly different 5-year surviva rates: low risk (68%), intermediate risk (44%), and high risk (28%) Conclusion: To our knowledge, this study includes the largest cohort of patients with advanced-stage MF/SS and identifies markers with independent prognostic value, which, used together in a prognostic ndex, may be useful to stratify advanced-stage patients.

UR - http://www.scopus.com/inward/record.url?scp=84948423157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948423157&partnerID=8YFLogxK

U2 - 10.1200/JCO.2015.61.7142

DO - 10.1200/JCO.2015.61.7142

M3 - Article

C2 - 26438120

AN - SCOPUS:84948423157

SN - 0732-183X

VL - 33

SP - 3766

EP - 3773

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 32

ER -

Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P et al. Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and sézary syndrome: Effect of specific prognostic markers on survival and development of a prognostic model. Journal of Clinical Oncology. 2015 Nov 10;33(32):3766-3773. doi: 10.1200/JCO.2015.61.7142

Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and sézary syndrome: Effect of specific prognostic markers on survival and development of a prognostic model

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this